Intensive management of patients with DKD including control of blood glucose and blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS), and inhibition of the sodium-glucose cotransporter 2 (SGLT2) may slow the progression of the disease. This evidence concerns the gene SLC5A2 and diabetic kidney disease.